Analogies for Aurinia Pharmaceuticals (AUPH):

• Vertex Pharmaceuticals for lupus nephritis.
• An emerging Biogen, but focused on specific autoimmune diseases like lupus nephritis.

• LUPKYNIS: A therapy for the treatment of adult patients with active lupus nephritis.

Aurinia Pharmaceuticals (AUPH), as a commercial-stage biopharmaceutical company selling a prescription drug (LUPKYNIS), primarily sells its product to other companies within the pharmaceutical supply chain rather than directly to individuals. The major customers for such companies are typically large pharmaceutical wholesalers and specialty pharmacies.

Therefore, Aurinia Pharmaceuticals' major customers are likely to include:

• Pharmaceutical Wholesalers: These companies purchase drugs in bulk and distribute them to hospitals, pharmacies, and clinics across the country. Key players in this sector often represent a significant portion of a biopharmaceutical company's sales. Examples include:
  • McKesson Corporation (NYSE: MCK)
  • Cencora (formerly AmerisourceBergen Corporation) (NYSE: COR)
  • Cardinal Health, Inc. (NYSE: CAH)
• Specialty Pharmacies: For drugs like LUPKYNIS, which may require specific handling, patient support, or are high-cost, sales often go through a network of specialty pharmacies. These pharmacies manage and dispense complex or high-cost medications directly to patients, often coordinating with insurance providers and healthcare professionals.

• Thermo Fisher Scientific Inc. (TMO)
• Catalent Inc. (CTLT)
• Sterling Pharma Solutions Limited

Peter Greenleaf, President, Chief Executive Officer and Director

Mr. Greenleaf has served as President, Chief Executive Officer, and Director of Aurinia Pharmaceuticals since 2019. He brings over 20 years of experience leading pharmaceutical and biotech firms. Notably, he was the Chairman and CEO of Sucampo Pharmaceuticals, Inc. from 2014 to 2018, leading it through a successful sale to Mallinckrodt plc for $1.2 billion. Prior to that, he served as CEO and Director of Cerecor Inc. from 2018 to 2019, and as President of MedImmune, Inc. (now AstraZeneca PLC), the global biologics arm of AstraZeneca, from 2006 to 2013. He also led MedImmune Ventures, Inc., a venture capital fund, where he guided investments in emerging biopharmaceutical and diagnostic companies.

Joe Miller, Chief Financial Officer

Mr. Miller has served as Chief Financial Officer of Aurinia Pharmaceuticals since 2020, bringing over two decades of experience in financial leadership within the health sciences, biotech, and pharmaceutical sectors. Most recently, from 2018 to 2020, he was the Chief Financial Officer, Principal Executive Officer, and Corporate Secretary at Cerecor Inc., where he oversaw company acquisitions and a strategic divestiture of a commercial portfolio. Before Cerecor, he was the Vice President of Finance at Sucampo Pharmaceuticals, Inc. from 2015 to 2018, where he was instrumental in building the finance organization, which culminated in its $1.2 billion merger with Mallinckrodt. He is also a Certified Public Accountant.

Max Donley, Chief Operating Officer

Mr. Donley was appointed Chief Operating Officer of Aurinia Pharmaceuticals in 2024, having previously served as Executive Vice President, Operations and Strategy from 2019 to 2024. His prior experience includes serving as Global Head, Human Resources, Information Technology and Facilities at Senseonics Holdings, Inc. from 2018 to 2019. From 2014 through its acquisition in 2018, Mr. Donley was Executive Vice President of Global Human Resources, Information Technology and Corporate Strategy at Sucampo Pharmaceuticals, Inc. He also held the role of Executive Vice President, Human Resources and Corporate Affairs at MedImmune, Inc. (now AstraZeneca PLC) from 2000 to 2013.

Greg Keenan, M.D., Senior Vice President, Chief Medical Officer

Dr. Keenan has served as Aurinia's Senior Vice President, Chief Medical Officer since 2023. Prior to joining Aurinia, he held various positions at ValenzaBio, Inc. from 2021 to 2023.

Scott Habig, Chief Commercial Officer

Mr. Habig joined Aurinia Pharmaceuticals as Chief Commercial Officer in July 2022. He brings over 20 years of global and U.S. sales and marketing experience, with significant expertise in the Rheumatology and Lupus markets. Before Aurinia, he spent 10 years at UCB, Inc., where his most recent role was Head of Global SLE. Mr. Habig also served as Vice President, Sales at Human Genome Sciences, where he was responsible for developing sales infrastructure and leading a major lupus drug launch. Earlier in his career, he spent nine years at Centocor, Inc., where his leadership in sales and marketing strategies helped transform a multi-million-dollar pipeline into a multi-billion-dollar product.

1. Heavy Reliance on LUPKYNIS

Aurinia Pharmaceuticals is substantially dependent on the commercial success of LUPKYNIS, its sole approved product, which accounts for over 95% of its total revenue. Any factors adversely affecting LUPKYNIS's market performance, regulatory status, or demand could have a disproportionate and significant negative impact on the company's financial results and overall business.

2. Competitive Threats

The market for lupus nephritis treatments is highly competitive, with LUPKYNIS facing challenges from both existing and newly approved therapies. While LUPKYNIS is the first FDA-approved oral therapy for lupus nephritis, it competes with injectable treatments such as GSK's BENLYSTA® and Roche's Gazyva® (approved in October 2025 for lupus nephritis). Emerging CAR-T therapies and other biologics also pose a threat, potentially eroding LUPKYNIS's market share and limiting its growth.

3. Patent Expiration and Litigation

LUPKYNIS is subject to patent challenges and eventual patent expiration, which could lead to generic competition. Although some patents, particularly those related to dosing protocols, may extend protection until 2037, the drug has already faced patent litigation. The earliest estimated generic launch date could be December 7, 2037, or potentially as early as October 17, 2027, if patent challenges are successful. The entry of cheaper generic versions could significantly reduce Aurinia's market share and profitability.

One clear emerging threat for Aurinia Pharmaceuticals and its product LUPKYNIS (voclosporin) is **Telitacicept (RC18)**, developed by RemeGen. Telitacicept is a dual inhibitor of B-cell activating factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), offering a different mechanism of action for autoimmune diseases. It is already approved in China for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN). RemeGen is currently conducting global Phase 3 clinical trials for SLE and Phase 3 trials for LN in China with aspirations for broader international market entry. If Telitacicept achieves global regulatory approvals for lupus nephritis, it would introduce a significant, directly competitive therapeutic option into the market, potentially challenging LUPKYNIS's market share due to its novel mechanism of action and established efficacy in certain markets.

• The global lupus nephritis market was valued at approximately USD 2.3 billion in 2025 and is predicted to reach USD 5.6 billion by 2034.
• In 2024, the global lupus nephritis market size was estimated at USD 2314.5 million, with projections to increase to USD 4176.95 million by 2031.
• For the 7 Major Markets (7MM), which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, the lupus nephritis market was valued at approximately USD 1,958 million in 2025 and is projected to grow to USD 4,088 million by 2034.
• The United States holds a significant portion of this market, with an estimated market size of USD 730.46 million in 2024. North America, overall, accounted for over 40% of the global revenue, with a market size of USD 925.80 million in 2024. The U.S. lupus nephritis treatment industry is predicted to grow at a Compound Annual Growth Rate (CAGR) of 12.5% from 2025 to 2035.

Aurinia Pharmaceuticals (AUPH) is expected to drive future revenue growth over the next 2-3 years through several key factors:

1. Increased Patient Adoption and Adherence for LUPKYNIS: The company's primary revenue driver is its flagship product, LUPKYNIS, for lupus nephritis. Aurinia Pharmaceuticals expects continued strong commercial momentum for LUPKYNIS, driven by growth in patient numbers, as well as high adherence and persistency rates among existing patients. Management has indicated seeing "growth across patients" and "very solid and continued adherence to the product and persistency." For 2026, the company projects LUPKYNIS net product sales to be between $305 million and $315 million, representing a 12-16% increase over 2025.
2. Favorable Impact of Updated Treatment Guidelines: Recent updates to the American College of Rheumatology (ACR) lupus nephritis treatment guidelines emphasize early and aggressive treatment, recommending the incorporation of drugs like LUPKYNIS into first-line therapy to preserve kidney function. These updated guidelines are anticipated to further drive the adoption and utilization of LUPKYNIS, contributing significantly to revenue growth.
3. Advancement of the Aritinercept Clinical Pipeline: Aurinia Pharmaceuticals is actively developing aritinercept, a pipeline asset targeting multiple autoimmune diseases. The company initiated one clinical study for aritinercept and plans to commence another in the first half of 2026. This strategic focus on advancing its pipeline, particularly aritinercept, aims to diversify Aurinia's product offerings and create new revenue streams beyond LUPKYNIS in the medium term.
4. International Expansion through Collaboration: While LUPKYNIS sales primarily contribute to U.S. revenue, the collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. presents opportunities for international expansion. Although a $10 million milestone payment for LUPKYNIS regulatory approval in Japan was recognized in 2024, the ongoing partnership with Otsuka could lead to further market penetration and revenue contributions from ex-U.S. territories as LUPKYNIS gains approvals and commercial traction in new regions.

Share Repurchases

• Aurinia's Board of Directors approved a share repurchase program of up to $150 million, with purchases commencing on February 21, 2024.
• An additional $150 million was authorized for the share repurchase plan in July 2025.
• By December 31, 2025, the company had repurchased 12.2 million common shares for $98.2 million during that year. By February 26, 2026, a total of 18,302,352 shares, valued at $138.58 million, had been repurchased under the program announced in February 2024.

Share Issuance

• No significant share issuances were reported within the last 3-5 years (March 2021 - March 2026). However, in July 2020, just prior to this period, Aurinia completed a public offering of common shares, raising approximately US$200 million in gross proceeds.

Inbound Investments

• Aurinia has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of LUPKYNIS in territories including Japan, the E.U., the U.K., and Switzerland.
• In the fourth quarter of 2025, Aurinia received a $10 million milestone payment related to LUPKYNIS's regulatory approval in Japan.
• In June 2023, the Board of Directors initiated an exploration of strategic alternatives, which could include a potential sale, merger, or other strategic transaction to enhance shareholder value.

Capital Expenditures

• Capital expenditures for Aurinia Pharmaceuticals were -$252,000 in the last 12 months (as of early 2026).
• Cash from investing activities for 2025 was USD -32.8 million.